Modified vaccinia virus ankara for the vaccnation of neonates

Abstract

The invention concerns the use of a virus for the preparation of a medicament for the vaccination or treatment of a human, wherein the virus is capable of infecting the cells of the human, but not capable of being replicated to infectious progeny virus in the human. The virus is preferably a Modified Vaccinia Virus Ankara.

1 - 59 . (canceled) 
     
     
         60 . A method of immunizing a human with an MVA virus comprising administering a first, priming inoculation and a second, boosting inoculation of the MVA virus to the human;
 wherein the MVA prime/MVA boost regime induces the same or higher CTL response than a DNA prime/MVA boost regime.   
     
     
         61 . The method of  claim 60 , wherein the MVA virus is a recombinant MVA virus. 
     
     
         62 . The method of  claim 60 , wherein the human is a neonate. 
     
     
         63 . The method of  claim 61 , wherein the human is a neonate. 
     
     
         64 . The method of  claim 61 , wherein the recombinant MVA virus encodes a heterologous viral antigen. 
     
     
         65 . The method of  claim 63 , wherein the recombinant MVA virus encodes a heterologous viral antigen. 
     
     
         66 . The method of  claim 61 , wherein the recombinant MVA virus encodes a tumor antigen. 
     
     
         67 . The method of  claim 63 , wherein the recombinant MVA virus encodes a tumor antigen. 
     
     
         68 . The method of  claim 61 , wherein the recombinant MVA virus encodes a bacterial antigen. 
     
     
         69 . The method of  claim 63 , wherein the recombinant MVA virus encodes a bacterial antigen. 
     
     
         70 . The method of  claim 61 , wherein the recombinant MVA virus encodes a fungal antigen. 
     
     
         71 . The method of  claim 63 , wherein the recombinant MVA virus encodes a fungal antigen. 
     
     
         72 . The method of  claim 60 , wherein the MVA virus is MVA 575. 
     
     
         73 . The method of  claim 60 , wherein the MVA virus is MVA-BN. 
     
     
         74 . The method of  claim 60 , wherein the MVA virus does not replicate in the immunized human. 
     
     
         75 . The method of  claim 61 , wherein the MVA virus does not replicate in the immunized human. 
     
     
         76 . The method of  claim 62 , wherein the MVA virus does not replicate in the immunized human. 
     
     
         77 . The method of  claim 63 , wherein the MVA virus does not replicate in the immunized human. 
     
     
         78 . The method of  claim 60 , wherein the MVA virus shows only residual replication activity that is controlled by the immune system of the immunized human. 
     
     
         79 . The method of  claim 61 , wherein the MVA virus shows only residual replication activity that is controlled by the immune system of the immunized human. 
     
     
         80 . The method of  claim 62 , wherein the MVA virus shows only residual replication activity that is controlled by the immune system of the immunized human. 
     
     
         81 . The method of  claim 63 , wherein the MVA virus shows only residual replication activity that is controlled by the immune system of the immunized human.